... with biopsy and 118,396 matched patients without biopsy were analyzed. The incidence per 1,000 person-years for hepatocellular carcinoma (HCC) was 0.22 versus 2.18, cirrhosis 29.75 versus 90.44, and hepatic decompensation 15.84 versus 28.25 compared patients with and without biopsy. In multivariable analysis...

... interstitial brachytherapy (iBT) radiotherapy has been established in the treatment of liver tumors. With iBT, hepatocellular carcinoma (HCC) lesions can be treated beyond the limits of thermal ablation (i.e., size and location). However, a comprehensive analysis of the efficacy of iBT in patients within...

...Andreas Teufel; Masatoshi Kudo; Yuquan Qian; Jimmy Daza; Isaac Rodriguez; Christoph Reissfelder; Ezequiel Ridruejo; Matthias P. Ebert Background: Hepatocellular carcinoma (HCC) remains a significant global health burden with a high mortality rate. Over the past 40 years, significant progress has...

..., a thrombopoietin receptor agonist, can increase the platelet count. This study assessed whether lusutrombopag reduces the risk of hemoperitoneum following percutaneous radiofrequency ablation for hepatocellular carcinoma, compared with platelet transfusion. Methods: Participants in the present study comprised...

...Egidijus Morkunas; Evelina Vaitkeviciute; Ruta Inciuraite; Juozas Kupcinskas; Alexander Link; Jurgita Skieceviciene; Marianna Alunni-Fabbroni; Kerstin Schütte; Peter Malfertheiner; Greta Varkalaite; Jens Ricke Introduction: Early diagnosis of hepatocellular carcinoma (HCC) as well as evaluation...

.... [email protected] 11 03 2022 13 12 2022 16 01 2023 Hepatocellular carcinoma Liver transplantation Immunotherapy Anti-vascular endothelial growth factor Downstaging © 2023 S. Karger AG, Basel Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved...

...Maximilian Thormann; Franziska Heitmann; Vanessa Wrobel; Constanze Heinze; Christine March; Peter Hass; Robert Damm; Alexey Surov; Maciej Pech; Jazan Omari Introduction: Interstitial brachytherapy (iBT) is an effective treatment for hepatocellular carcinoma (HCC). Identification of prognostic...

... after the procedure at 1, 3, and 5 years was 94.2%, 74.0%, and 63.5%, respectively, and 10 patients died of hepatocellular carcinoma ( n = 6), liver failure ( n = 1), sepsis ( n = 1), and unknown reasons ( n = 2). The estimated glomerular filtration rate (eGFR) level was proved to be a significant poor...

...Xingwei Wang; Jing Zhang; Fang Luo; Yaolin Shen Background: Although the involvement of circular RNA Circ_0071662 in bladder cancer and esophageal cancer has been reported, its role in hepatocellular carcinoma (HCC) is unclear. The presented research aimed to study its role in HCC. Methods...

...Yu Zhang; Hua Cai; Ming-Hao Wu; Dan-Hua Zhu; Xiang-Yang Wang; Zhi-Yuan Chen; Li Yang; Peng Liu; Zhan Liu Background: Hepatocellular carcinoma (HCC) is a leading cancer worldwide. miRNA has been linked to cancer processes. We want to figure out what the underlying mechanism and functions of miR-3682...

...Jiancun Hou; Zhe Qiang; Yang Li; Yamin Zhang Background: Currently, enough studies with aggregated study-level data have demonstrated that there was no clinically meaningful difference in the risk of hepatocellular carcinoma (HCC) between patients who received entecavir and patients who received...

... and curative treatment options, surveillance imaging for hepatocellular carcinoma (HCC) must remain of quality and without substantial limitations in liver visualization. However, the prevalence of limited liver visualization during HCC surveillance imaging has not been systematically assessed. Utilizing...

...Dan Cao; Huan Liu; Lang Bai; Hong Tang Background: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide, accounting for more than 700,000 deaths annually. Epithelial-mesenchymal transition (EMT) is posited to contribute to HCC progression. We, therefore...

...Yuquan Qian; Baojiang Liu; Christel Weiss; Xu Zhu; Andreas Teufel Introduction: Hepatocellular carcinoma (HCC) may occur with several simultaneous tumor foci in the liver (multifocal HCC). Molecular biology indicated that the larger the distance between two tumor nodules, the more those two nodules...

... for chronic hepatitis B (CHB) later develop adverse outcomes such as cirrhosis and hepatocellular carcinoma (HCC). Our aim was to determine whether current practice guidelines adequately identify CHB patients who will benefit from antiviral therapy. Methods: We performed a retrospective cohort study comparing...

...Yosuke Inukai; Kenta Yamamoto; Takashi Honda; Takanori Ito; Norihiro Imai; Yoji Ishizu; Masanao Nakamura; Hiroki Kawashima; Masatoshi Ishigami Introduction: Lenvatinib has been widely used for the treatment of advanced hepatocellular carcinoma (HCC). Some adverse events, including diarrhea, have...

..., instructions or products referred to in the content or advertisements. Hepatocellular carcinoma Liver fibrosis Prognosis Mortality Diabetes Affecting more than 250 million individuals worldwide, chronic infection with the hepatitis B virus (HBV) is a leading cause of adverse liver-related...

... of response to transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). Methods: Scopus database, Embase database, and MEDLINE library were scanned for connections between pre- and posttreatment ADC values of HCC and response to TACE. Six studies qualified for inclusion...

...Florian P. Reiter; Najib Ben Khaled; Liangtao Ye; Changhua Zhang; Max Seidensticker; Mark op den Winkel; Gerald Denk; Andreas Geier; Enrico N. De Toni Background: Due to the number of emerging new treatment options, the systemic treatment of hepatocellular carcinoma (HCC) is rapidly changing. We...

...Osman Öcal; Daniel Rössler; Jens Ricke; Max Seidensticker Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths, and radiological imaging and locoregional therapies are essential for the management of patients with HCC. Summary: In cirrhotic patients...